Rukmini Sivaraman sold $153k of NTNX
Chief Financial Officer at Nutanix, Inc.. 2,100 shares at an average of $72.73, traded Jun 16, 2025, filed Jun 17, 2025.
Score components
- +22RoleCFO
- +11Trade size$153k at market
- 0Share of holdings soldSold 1.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-087519, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +2,588 | $0.00 | $0 | 203,257 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,760 | $0.00 | $0 | 208,017 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +6,250 | $0.00 | $0 | 214,267 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,766 | $0.00 | $0 | 219,033 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +2,977 | $0.00 | $0 | 222,010 | Jun 17, 2025 |
| Jun 15, 2025 | FTax withholding Class A Common Stock10b5-1 | -10,840 | $72.13 | $782k | 211,170 | Jun 17, 2025 |
| Jun 16, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,900 | $72.68 | $138k | 209,270 | Jun 17, 2025 |
| Jun 16, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -200 | $73.25 | $15k | 209,070 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -2,588 | $0.00 | $0 | 2,589 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -4,760 | $0.00 | $0 | 19,041 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -6,250 | $0.00 | $0 | 31,250 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -4,766 | $0.00 | $0 | 42,888 | Jun 17, 2025 |
| Jun 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -2,977 | $0.00 | $0 | 38,708 | Jun 17, 2025 |
Related signals
Other insiders at Nutanix, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Nutanix, Inc. | Teresa Gayle Sheppard director | $258k 3,500 shares | -13% | |
| 55Moderate | Nutanix, Inc. | Rajiv Ramaswami Chief Executive Officer | $29M 400,000 shares | -49% | |
| 80Strong | Nutanix, Inc. | Tarkan Maner President and CCO | $4.8M 69,778 shares | -67% | |
| 25Weak | Nutanix, Inc. | Rukmini Sivaraman Chief Financial Officer | $2.7M 38,139 shares | -10% | |
| 50Moderate | Nutanix, Inc. | Rajiv Ramaswami President and CEO | $11M 144,707 shares | -22% | |
| 28Weak | Nutanix, Inc. | Teresa Gayle Sheppard director | $268k 3,500 shares | -14% | |
| 52Moderate | Nutanix, Inc. | Brian Martin Chief Legal Officer | $784k 10,241 shares | -66% | |
| 18Weak | Nutanix, Inc. | Rukmini Sivaraman Chief Financial Officer | $892k 11,391 shares | -4% | |
| 24Weak | Nutanix, Inc. | Rajiv Ramaswami President and CEO | $144k 1,925 shares | -0% | |
| 54Moderate | Nutanix, Inc. | Virginia Gambale director | $546k 7,000 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.